Comparative Pharmacology
Head-to-head clinical analysis: AMBRISENTAN versus LETAIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBRISENTAN versus LETAIRIS.
AMBRISENTAN vs LETAIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist (ERA) that selectively binds to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle, blocking endothelin-1-mediated vasoconstriction and proliferation.
Ambrisentan is an endothelin receptor antagonist that selectively inhibits endothelin-1 (ET-1) binding to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle cells, reducing vasoconstriction and smooth muscle proliferation.
10 mg orally once daily, with or without food, for patients not receiving cyclosporine. For patients receiving cyclosporine, reduce dose to 5 mg once daily.
5 mg orally once daily, with or without food; may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Clinical Note
moderateAmbrisentan + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Methylphenidate
"Ambrisentan may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateAmbrisentan + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Erythromycin
Terminal elimination half-life is approximately 9 hours (range 4–20 hours) in healthy subjects; no significant accumulation is observed with once-daily dosing.
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) in healthy adults.
Primarily via nonrenal pathways, with fecal excretion accounting for approximately 77% of a radiolabeled dose (as unchanged drug and metabolites) and renal excretion for about 22% (mostly as metabolites).
Primarily via biliary/fecal elimination (approximately 80% of metabolites and unchanged drug; ~20% renal as metabolites).
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist
"The metabolism of Erythromycin can be decreased when combined with Ambrisentan."